Loading...

SPRY ARS PHARMACEUTICALS INC Expansion Plans 8-K Filing

RS P

SPRY

ARS PHARMACEUTICALS INC

(SPRY)

2024 8-K

Show Summary

Show Summary

Financial Statements

Investor Meetings

Financial Results

Financial Update

Financial Results

Collaboration Agreement

Supply Agreement

Manufacturing Agreement

Financial Results Announcement

Corporate Presentation Upda...

Presentation Update

Financial Results Announcement

Financial Results Announcement

Financial Update

Financial Results Announcement

Presentation Update

Financial Results Announcement

Annual Meeting of Stockholders

Regulation FD Disclosure

Financial Results Announcement

FDA Briefing Documents for ...

Financial Results Announcement

Presentation Update

Termination Agreement with ...

Financial Update

External Links:

ARS Pharmaceuticals entered a collaboration agreement with ALK-Abell A/S for the development and commercialization of epinephrine nasal spray, receiving an upfront payment of $145 million and potential milestone payments totaling up to $320 million.

AI Assistant

ARS PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.